Poisons centres and the reporting of adverse drug events: The case for further development

Drug Safety

Volumn 30, Issue 3, 2007, Pages 191-194

  Volans, Glyn N ^a,d   Karalliedde, Lakshman ^b,c   Wiseman, Heather M ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HUMAN; MEDICAL PRACTICE; POISON CENTER; PRIORITY JOURNAL;

EID: 33947259971     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730030-00002     Document Type: Editorial

References (34)

1. Edwards IR. What is drug safety? Celebrating 20 years of the Drug Safety journal. Drug Saf 2006; 29: 461-5
2. Buckley NA, Smith AJ. Evidence-based medicine in toxicology: where is the evidence? Lancet 1996; 347 (9009): 1067-9
3. National Collaborating Centre for Mental Health. Self-harm: short-term physical and psychological management and secondary prevention of self-harm in primary and secondary care. London: The British Psychological Society, 2004
4. Egberts AC, de Koning FH, Meyboom RH, et al. ADR related questions received by a telephone medicines information service and ADRs received by a spontaneous ADR reporting system: a comparison regarding patients and drugs. Pharmacoepidemiol Drug Saf 1997; 6 (4): 269-76
5. Ponampalam R, Anantharaman V. The need for drug and poison information: the Singapore physicians' perspective. Singapore Med J 2003; 44 (5): 231-42
6. Mey C, Hentschel H, Hippius M, et al. Documentation and evaluation of adverse drug reactions: contribution from a poison information centre. Int J Clin Pharmacol Ther 2002; 40 (3): 102-7
7. Fehr JM, Vicas IM-O. Unintentional adult medication exposures: an unrecognized phenomenon. Clin Toxicol 2005; 43 (6): 717
8. Butera R, Georgatos J, Arrigoni S, et al. Adverse reactions to intravenous acetylcysteine, effects of reducing the infusion rate of the loading dose. Clin Toxicol 2005; 43 (5): 437
9. Mégarbane B, Andriantafika G, Berleur MP, et al. Toxic alcohol exposures and poisoning treated with fomepizole during a 2 year post marketing surveillance in France [abstract]. Clin Toxicol 2005; 43 (5): 512-3
10. World Health Organization. Guidelines for poison control [online]. Available from URL: http://www.who.int/ipcs/publications/training_poisons/ guidelines_poison_control/en/index5. html [Accessed 2007 Jan 3]
11. Descotes J, Testud F. Toxicovigilance: a new approach for the hazard identification and risk assessment of toxicants in human beings. Toxicol Appl Pharmacol 2005; 207: S599-603
12. World Health Organization. The importance of pharmacovigilance, safety monitoring of medicinal products. Geneva: WHO, 2002
13. Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score, grading of acute poisoning. Clin Toxicol 1998; 36 (3): 205-313
14. Chyka PA, McCommon SW. Reporting of adverse drug reactions by poison control centres in the US. Drug Saf 2000; 23 (1): 87-93
15. Fraunhofer Institute Systems and Innovation Research in collaboration with the Coordination Centre for Clinical Studies at the University Hospital of Tuebingen. An assessment of the community system of pharmacovigilance [online]. Available from URL: http://ec.europa.eu/enterprise/pharmaceuticals/ pharmacovigilance_acs/docs/acs_consultation_final.pdf. [Accessed 2007 Jan 18]
16. Onyon L. Poisons centres and adverse drug reaction reporting: opportunities for greater collaboration. WHO Pharmaceuticals Newsletter 2002; 4: 13-4
17. Abstracts from the North American Congress of Clinical Toxicology Annual Meeting 2005. Clin Toxicol 2005; 43 (6): 631-777
18. Abstracts from the North American Congress of Clinical Toxicology Annual Meeting 2006. Clin Toxicol 2006; 44 (5): 625-783
19. European Association of Poisons Centres and Clinical Toxicologists XXV International Congress, 2005. Clin Toxicol 2005; 43 (5): 387-538
20. Forrester MB. Celecoxib exposures reported to Texas poison control centers from 1999 to 2004. Hum Exp Toxicol 2006; 25 (5): 261-6
21. Halcomb SE, Nelson LS, Shah C, et al. Telithromycin induced cholinergic crisis in myasthenia gravis. Clin Toxicol 2005; 43 (6): 632
22. Wong ICK, Besag FMC, Santosh PJ, et al. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004; 27 (13): 991-1000
23. Liang IE, Bird SB, Brush DE, et al. Acute myocardial infarction after infusion of the experimental drug TLK199. Clin Toxicol 2006; 44: 658
24. Woolf AD. Safety evaluation and adverse events monitoring by poison control centers: a framework for herbs and dietary supplements. Clin Toxicol 2006; 44 (5): 625-783
25. Schwamer RA, Hoffman RS, Howland MA, et al. What role does (should?) the PCC play regarding the medication safety of drugs administered off-label. Clin Toxicol 2006; 44: 710
26. BNF for Children. General guidance: supply of medicines. 2nd ed. London: BMJ Publishing Group, Ltd, Royal pharmaceutical Society of Great Britain, RCPH Publications Ltd, 2006
27. Robinson RF, Baker SD, Casavant MJ, et al. Therapeutic error: carboprost tromethamine given to a newborn intramuscularly. Clin Toxicol 2005; 43 (6): 636
28. Burda A, Razo M, Wahl M. Therapeutic errors with ranitidine in paediatric patients. Clin Toxicol 2005; 43 (6): 639
29. Powers M, Stremski E, Dellinger J, et al. Medication errors in children under 12 months of age. Clin Toxicol 2005; 43 (6): 650-1
30. Lewis TV, Schaeffer SE, Hagemann TM, et al. Misleading product packaging contributing to salicylate toxicity in an infant. Clin Toxicol 2005; 43 (6): 651
31. Tzimenatos L, Bond GR. Cases of severe injury or death in children resulting from unintentional therapeutic error in a health care facility. Clin Toxicol 2005; 43 (6): 651-2
32. Fareed FN, Chan GM, Hoffman FS. Fatal cocaine metoprolol interaction. Clin Toxicol 2005; 43 (6): 641
33. Hugman B. The Erice Declaration: the critical role of communication in drug safety. Drug Saf 2006; 29 (1): 91-3
34. Edwards IR. The WHO World Alliance for Patient Safety. Drug Saf 2005; 28 (5): 379-86